GOLDENWELL BIOTECH, INC. reported first-quarter 2026 results, remaining pre-revenue with Revenue of $0 and a net loss of $17606; diluted earnings per share were $(0.00018), an improvement from the year-ago quarter.
Financial Highlights
- Revenue: $0 for Q1 2026, unchanged from $0 in Q1 2025.
- Net income: Net loss of $17,606 for Q1 2026, improved from a net loss of $38,536 in Q1 2025.
- Diluted EPS: $(0.00018) for Q1 2026 (basic and diluted), improved from $(0.00039) in Q1 2025.
Business Highlights
- The company remains pre-revenue while building operations and sales capability; no active sales channels during the quarter.
- Early-stage corporate formation and start-up activities were expensed, yielding limited operational traction to date.
- Plans include constructing manufacturing facilities and training a workforce, with an estimated cost of roughly $5M and about one year to execute.
- Management is focused on securing debt or equity financing to fund the commercial launch and scale manufacturing and sales.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.